VIVUS, Inc. – Product Pipeline Review – H2 2011

VIVUS, Inc. - Product Pipeline Review - H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “VIVUS, Inc. - Product Pipeline Review - H2 2011” provides data on the VIVUS, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, VIVUS, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from VIVUS, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

• VIVUS, Inc. - Brief VIVUS, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
• Review of current pipeline of VIVUS, Inc. human therapeutic division.
• Overview of pipeline therapeutics across various therapy areas.
• Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of VIVUS, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
• Recent updates of the VIVUS, Inc.’s pipeline in the last quarter.
• Key discontinued and dormant projects.
• Latest news and deals relating to the products.

Reasons to buy

• Evaluate VIVUS, Inc.’s strategic position with total access to detailed information on its product pipeline.
• Assess the growth potential of VIVUS, Inc. in its therapy areas of focus.
• Identify new drug targets and therapeutic classes in the VIVUS, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
• Exploit collaboration and partnership opportunities with VIVUS, Inc..
• Avoid Intellectual Property Rights related issues.
• Explore the dormant and discontinued projects of VIVUS, Inc. and identify potential opportunities in those areas.

Contents

VIVUS, Inc. Snapshot
VIVUS, Inc. Overview
Key Information
Key Facts
VIVUS, Inc. – Research and Development Overview
Key Therapeutic Areas
VIVUS, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
VIVUS, Inc. – Pipeline Products Glance
VIVUS, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
VIVUS, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
VIVUS, Inc. – Drug Profiles
Avanafil
Avanafil + Amlodipine
Avanafil + Enalapril
Qnexa
VIVUS, Inc. – Pipeline Analysis
VIVUS, Inc. – Pipeline Products by Therapeutic Class
VIVUS, Inc. - Pipeline Products By Target
VIVUS, Inc. – Pipeline Products by Route of Administration
VIVUS, Inc. – Pipeline Products by Molecule Type
VIVUS, Inc. – Recent Pipeline Updates
VIVUS, Inc. - Dormant Projects
VIVUS, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Alibra
VIVUS, Inc. – Company Statement
VIVUS, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Company's Recent Developments
VIVUS, Inc., Recent Developments
Sep 29, 2011: VIVUS To Present Additional Analysis Data From Two-Year Sequel Study Of QNEXA At The 2011 Annual Scientific Meeting Of Obesity Society
Sep 26, 2011: VIVUS To Present Poster On Topiramate Exposure And Fetal Outcomes In Migraine Patients At 136th ANA Annual Meeting
Oct 17, 2011: VIVUS Resubmits Qnexa NDA To FDA
Nov 16, 2007: VIVUS Initiates Second Qnexa Pivotal Phase III Trial In Obese Patients
Sep 16, 2011: Data From QNEXA Sequel Study Featured At 47th EASD Annual Meeting
Sep 15, 2011: VIVUS Provides Regulatory Update On QNEXA
Nov 14, 2011: VIVUS Presents New Analyses From Phase III Study Of Avanafil At Annual Meeting Of Sexual Medicine Society of North America
Sep 13, 2011: VIVUS Announces Positive Results From Avanafil Phase III Study In Diabetics Presented At 47th EASD Annual Meeting
Nov 10, 2011: VIVUS To Present Data On Avanafil At Sexual Medicine Society Of North America Meeting
Aug 05, 2011: VIVUS To Present Additional Data From QNEXA Phase III Program At American Association of Diabetes Educators Annual Meeting
Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa
Nov 03, 2011: VIVUS's Qnexa Phase III Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Oct 03, 2011: Vivus Highlights Long-Term Benefits Of Qnexa At Obesity 2011
Sep 01, 2011: VIVUS Announces FDA Acceptance Of Avanafil NDA For Treatment Of Erectile Dysfunction
Financial Deals Landscape
VIVUS, Inc., Deals Summary
VIVUS, Inc., Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
VIVUS Enters Into Licensing Agreement With KV Pharmaceutical
VIVUS Enters Into Licensing Agreement With Acrux
Equity Offering
VIVUS Completes Private Placement Of Common Shares For $45.8 Million
VIVUS Completes Public Offering Of $109 Million
VIVUS Completes Registered Direct Offering Of Common Stock For $65 Million
VIVUS Completes Registered Direct Offering Of $34 Million
VIVUS Completes Private Placement Of $12 Million
VIVUS Completes Public Offering Of $21 Million
Asset Transactions
Meda Completes The Acquisition Of MUSE From VIVUS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

VIVUS, Inc., Key Information
VIVUS, Inc., Key Facts
VIVUS, Inc. – Pipeline by Therapy Area and Indication, H2 2011
VIVUS, Inc. – Pipeline by Stage of Development, H2 2011
VIVUS, Inc. – Monotherapy Products in Pipeline, H2 2011
VIVUS, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
VIVUS, Inc. – Filed, H2 2011
VIVUS, Inc. - Phase II, H2 2011
VIVUS, Inc. - Phase I, H2 2011
VIVUS, Inc. - Pipeline By Therapeutic Class, H2 2011
VIVUS, Inc. - Pipeline By Target, H2 2011
VIVUS, Inc. – Pipeline By Route of Administration, H2 2011
VIVUS, Inc. – Pipeline By Molecule Type, H2 2011
VIVUS, Inc. – Recent Pipeline Updates, H2 2011
VIVUS, Inc. - Dormant Developmental Projects, 2010
VIVUS, Inc. - Discontinued Pipeline Products, 2010
VIVUS, Inc., Subsidiaries
VIVUS, Inc., Deals Summary
VIVUS Enters Into Licensing Agreement With KV Pharmaceutical
VIVUS Enters Into Licensing Agreement With Acrux
VIVUS Completes Private Placement Of Common Shares For $45.8 Million
VIVUS Completes Public Offering Of $109 Million
VIVUS Completes Registered Direct Offering Of Common Stock For $65 Million
VIVUS Completes Registered Direct Offering Of $34 Million
VIVUS Completes Private Placement Of $12 Million
VIVUS Completes Public Offering Of $21 Million
Meda Completes The Acquisition Of MUSE From VIVUS

LIST OF FIGURES

VIVUS, Inc. – Pipeline by Therapy Area and Indication, H2 2011
VIVUS, Inc. – Pipeline by Stage of Development, H2 2011
VIVUS, Inc. – Monotherapy Products in Pipeline, H2 2011
VIVUS, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
VIVUS, Inc. – Pipeline By Therapeutic Class, H2 2011
VIVUS, Inc. - Pipeline By Target, H2 2011 Skip to top